A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59-adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed
Latest Information Update: 17 Apr 2023
At a glance
- Drugs Adjuvanted cell based influenza vaccine seqirus (Primary) ; MF 59
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Seqirus
Most Recent Events
- 13 Apr 2023 Status changed from active, no longer recruiting to completed.
- 08 Oct 2022 Planned End Date changed from 1 May 2023 to 1 Apr 2023.
- 08 Oct 2022 Planned primary completion date changed from 1 May 2023 to 1 Oct 2022.